CrossrefInfokarte
PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
Clinical Ovarian Cancer · 2011
DOI: 10.1016/j.cloc.2012.02.002 ↗Abstract
Kein Abstract verfügbar.
EUVIMED